In a recent study, we have designed a liver-targeted siRNA against Acly (Aclysiran) by conjugating GalNAc and shown that Aclysiran attenuate hyperlipidemia and atherosclerosis comparable to Bempedoic acid 8. Here, ACLY is linked to hyperlipidemia.